After Unicycive Therapeutics had its drug application for oxylanthanum carbonate (OLC)
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Unicycive's CKD drug oxylanthanum carbonate gets a second FDA rejection over third-party manufacturing issues; shares drop ~50%…
The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading…
Viridian Therapeutics has scored an FDA
Unicycive Therapeutics ($UNCY) stock crashes over 46% as FDA rejects kidney disease drug NDA again over third-party manufacturing…
After submitting its timed-release version of a decades-old ADHD drug to the FDA nearly a year ago, Kansas City's Cingulate has…
As Amgen prepares to defend Tavneos’ market approval in the U.S., the company has received a bad omen overseas, with regulators…
